Clinical Trials Logo

Asthma, Allergic clinical trials

View clinical trials related to Asthma, Allergic.

Filter by:

NCT ID: NCT06063044 Completed - Atopic Dermatitis Clinical Trials

Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children

Start date: January 1, 2018
Phase:
Study type: Observational

Allergic diseases in children are major public health concerns due to their widespread and rising prevalence. The most classic pathway to trigger allergy is type I allergy mediated by immunoglobulin E(IgE), but the role of immunoglobulin G4(IgG4) in allergic diseases is still worth exploring.we have collected the data of allergic patients aged 0-14 years for retrospective cross-sectional analysis to evaluate the positive rates of total IgE, HDM IgE, FS-IgE and FS-IgG4. Meanwhile, investigators screened out patients who were treated with FS-IgG4-guided elimination diets with/without probiotics for more than 3 months to clarify the role of FS-IgG4 in childhood allergic diseases by assessing the improvement of clinical symptoms before and after treatment.

NCT ID: NCT06027073 Not yet recruiting - Asthma, Allergic Clinical Trials

Biologics and Sublingual Immunotherapy

BSIPL
Start date: May 1, 2024
Phase: Phase 4
Study type: Interventional

Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.

NCT ID: NCT05740748 Not yet recruiting - Asthma, Allergic Clinical Trials

Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

Asthma is a condition where small inhaled particles can cause inflammation in the lung leading to constriction of airways and wheeze. Mast cells are immune cells in airways that can release chemical causing constriction of the airways and wheeze. Tezepelumab is an injectable medication that improves asthma by stopping inflammation, but the effect on mast cells is not known. Tezepelumab was approved in Canada July 2022 for treatment of severe asthma. Tezepelumab is not approved for treatment of mild asthma by any health authority, except for use in research studies like this. This study will examine the effect of tezepelumab on mast cells and airway constriction to understand the mechanisms of asthma, and which patients will benefit most from drugs like tezepelumab.

NCT ID: NCT05720325 Recruiting - Asthma, Allergic Clinical Trials

Dupilumab Effects Against Aeroallergen Challenge

Start date: March 29, 2023
Phase: Phase 2
Study type: Interventional

The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.

NCT ID: NCT05478824 Recruiting - Obesity Clinical Trials

IL13 Signaling in Allergic Asthma

Start date: February 21, 2023
Phase:
Study type: Observational

This study will investigate the role of dupilumab in the treatment of asthma with comorbid obesity. It is hypothesized that in airway epithelial cells, unique transcriptomic and proteomic expression patterns distinguish allergic and non-allergic patients with asthma and obesity and drive significant differential responses to dupilumab. It is further hypothesized that dupilumab will increase interleukin-13 receptor alpha 2 (IL-13Rα2) levels and/or signaling activity on airway epithelial cells isolated from allergic asthma patients with obesity. This is a pre-clinical research study of dupilumab-induced gene and protein expression analyses in nasal airway epithelial cells of adults with asthma and comorbid obesity. The study primarily seeks to: 1) assess the effect of dupilumab on transcriptomes, phosphoproteomes and secretomes of well-differentiated, primary airway epithelial cells as a function IL-13R subunit expression and IL-13Ra2 signaling, in allergic and non-allergic asthma patients with obesity; and 2) test whether dupilumab-induced gene and protein changes significantly correlate with parameters of airway inflammation in allergic and non-allergic asthma.

NCT ID: NCT05352126 Not yet recruiting - Asthma, Allergic Clinical Trials

Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma.

PSIndAC
Start date: May 2022
Phase: N/A
Study type: Interventional

The main objective of this study is to evaluate, in real life, the efficacy of prolonged use (6 months) of Puressentiel Air Purifying Spray with 41 essential oils on the control of allergy-induced asthma in the homes of patients with mild to moderate asthma. This will be performed by evaluating the efficacy of prolonged use (6 months) in the indoor environment on the exacerbation and the symptoms of asthma in patients with mild to moderate asthma. The tolerance of the study patients to spraying in an indoor environment will also be analysed.

NCT ID: NCT04898283 Recruiting - Rhinoconjunctivitis Clinical Trials

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Start date: May 31, 2021
Phase: Phase 3
Study type: Interventional

A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis With or Without Mild to Moderate Asthma Sensitized to cupressaceae and grasses.

NCT ID: NCT04891237 Recruiting - Rhinoconjunctivitis Clinical Trials

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

Start date: June 14, 2021
Phase: Phase 3
Study type: Interventional

Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and olive

NCT ID: NCT04435990 Recruiting - Rhinoconjunctivitis Clinical Trials

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

MM09-SIT-023
Start date: October 6, 2020
Phase: Phase 3
Study type: Interventional

A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with mild to moderate asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides farinae.

NCT ID: NCT04109807 Suspended - Asthma, Allergic Clinical Trials

Effects of Low Dose Ozone on Airway Inflammatory Responses in Adults With Asthma - Sedentary Nasal Ozone (Asthma SNOZ)

Start date: December 16, 2019
Phase: N/A
Study type: Interventional

To determine if low levels of ozone (O3) encountered on a typical day in Chapel Hill will decrease spirometric values in mild asthmatics.